Literature DB >> 25585956

Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.

Ji-Young Kim1, Seung Woo Chung, Sang Yoon Kim, Youngro Byun.   

Abstract

PURPOSE: To overcome definite limitations of angiogenesis inhibitors such as insufficient therapeutic efficacy as a single drug and resisting or conflicting effect under chronic treatment, it is required to develop a new regimen to improve the therapeutic effect.
METHODS: The combination effect of a multi-targeting angiogenesis inhibitor (LHT7) and a selective cyclooxygenase-2 inhibitor (celecoxib) on neovascularization in tumor growth was studied both in vitro and vivo experiments.
RESULTS: While hypoxia-mediated COX-2 overexpression and macrophage recruitment were observed at LHT7-treated tumor tissues, it was well-controlled by the combination of celecoxib and LHT7. On the other hand, the in vitro tube formation and the in vivo tumor vessel formation and structure were inhibited by either LHT7 or celecoxib, but the inhibition effect was further enhanced by using them together. However, the combination therapy did not further enhance the inhibitory effect on tumor growth in terms of volume compared to single drug uses, which attributed not to increased cellular apoptosis but to decreased cell proliferation.
CONCLUSIONS: COX-2 inhibition could enhance the therapeutic effect of anti-angiogenic drugs both by inhibiting the inflammatory reactions induced by hypoxia and by altering the vascular stabilization that is mediated by an assembly with mural cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25585956     DOI: 10.1007/s11095-015-1623-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  34 in total

Review 1.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 2.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 3.  Targeting the tumour vasculature: insights from physiological angiogenesis.

Authors:  Alicia S Chung; John Lee; Napoleone Ferrara
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

Review 4.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

Authors:  Giampietro Gasparini; Raffaele Longo; Roberta Sarmiento; Alessandro Morabito
Journal:  Lancet Oncol       Date:  2003-10       Impact factor: 41.316

Review 5.  Controlling escape from angiogenesis inhibitors.

Authors:  Barbara Sennino; Donald M McDonald
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

Review 6.  Inflammation: gearing the journey to cancer.

Authors:  Joydeb Kumar Kundu; Young-Joon Surh
Journal:  Mutat Res       Date:  2008-03-16       Impact factor: 2.433

Review 7.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.

Authors:  Esak Lee; Yoo-Shin Kim; Sang Mun Bae; Sang Kyoon Kim; Shunji Jin; Seung Woo Chung; Myungjin Lee; Hyun Tae Moon; Ok-Cheol Jeon; Rang Woon Park; In San Kim; Youngro Byun; Sang Yoon Kim
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

Review 10.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

Authors:  Sonja Loges; Massimiliano Mazzone; Philipp Hohensinner; Peter Carmeliet
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  2 in total

1.  SERS spectral study of HAuCl4-cysteine nanocatalytic reaction and its application for detection of heparin sodium with label-free VB4r molecular probe.

Authors:  Xiaoliang Wang; Caina Jiang; Yanna Qin; Yutao Peng; Guiqing Wen; Aihui Liang; Zhiliang Jiang
Journal:  Sci Rep       Date:  2017-04-05       Impact factor: 4.379

Review 2.  The role of tumor microenvironment in resistance to anti-angiogenic therapy.

Authors:  Shaolin Ma; Sunila Pradeep; Wei Hu; Dikai Zhang; Robert Coleman; Anil Sood
Journal:  F1000Res       Date:  2018-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.